These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29992976)

  • 1. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
    Hartley JA; Flynn MJ; Bingham JP; Corbett S; Reinert H; Tiberghien A; Masterson LA; Antonow D; Adams L; Chowdhury S; Williams DG; Mao S; Harper J; Havenith CEG; Zammarchi F; Chivers S; van Berkel PH; Howard PW
    Sci Rep; 2018 Jul; 8(1):10479. PubMed ID: 29992976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates.
    Corbett S; Huang S; Zammarchi F; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2020 Sep; 19(9):1856-1865. PubMed ID: 32669316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
    Hartley JA
    Expert Opin Biol Ther; 2021 Jul; 21(7):931-943. PubMed ID: 32543981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate.
    Huang Y; Del Nagro CJ; Balic K; Mylott WR; Ismaiel OA; Ma E; Faria M; Wheeler AM; Yuan M; Waldron MP; Peay MG; Cortes DF; Roskos L; Liang M; Rosenbaum AI
    Anal Chem; 2020 Aug; 92(16):11135-11144. PubMed ID: 32459957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
    Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
    Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
    Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
    Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
    Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of PBD Dimers by Lipophilicity Manipulation.
    Cailleau T; Adams LR; Arora N; Kang GD; Masterson L; Patel N; Hartley JA; Mao S; Harper J; Howard PW
    Curr Top Med Chem; 2019; 19(9):741-752. PubMed ID: 30931859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.
    Gregson SJ; Howard PW; Gullick DR; Hamaguchi A; Corcoran KE; Brooks NA; Hartley JA; Jenkins TC; Patel S; Guille MJ; Thurston DE
    J Med Chem; 2004 Feb; 47(5):1161-74. PubMed ID: 14971896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
    Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
    Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.
    Tiberghien AC; Levy JN; Masterson LA; Patel NV; Adams LR; Corbett S; Williams DG; Hartley JA; Howard PW
    ACS Med Chem Lett; 2016 Nov; 7(11):983-987. PubMed ID: 27882195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity.
    Tiberghien AC; Vijayakrishnan B; Esfandiari A; Ahmed M; Pardo R; Bingham J; Adams L; Santos K; Kang GD; Pugh KM; Afif-Rider S; Vashisht K; Haque K; Tammali R; Rosfjord E; Savoca A; Hartley JA; Howard PW
    Mol Cancer Ther; 2023 Feb; 22(2):254-263. PubMed ID: 36722141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
    Gregson SJ; Howard PW; Hartley JA; Brooks NA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 2001 Mar; 44(5):737-48. PubMed ID: 11262084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.
    Staben LR; Chen J; Cruz-Chuh JD; Del Rosario G; Go MA; Guo J; Khojasteh SC; Kozak KR; Li G; Ng C; Lewis Phillips GD; Pillow TH; Rowntree RK; Wai J; Wei B; Xu K; Xu Z; Yu SF; Zhang D; Dragovich PS
    J Med Chem; 2020 Sep; 63(17):9603-9622. PubMed ID: 32787101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?
    Hartley JA
    Expert Opin Biol Ther; 2023; 23(11):1049-1052. PubMed ID: 37902460
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
    Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.